3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Kaitlyn Allen of MendIt, Miguel Calatayud of iwi, and Tatiana Fofanova of Koda Health. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to health tech — recently making headlines in Houston innovation.

Kaitlyn Allen, founder and chief strategy officer of MendIt

MendIt seeks to reduce textile waste by providing an easy-to-use app to make menders and customizers more accessible. Photo courtesy of MendIt

Kaitlyn Allen thought she had a great idea for a company — something that can help people repair clothing conveniently. And all of the pieces of the strategy already existed. There are plenty of seamstressing businesses around town, but not an easy way to navigate them. “

There’s a disconnect. There’s a market of people who potentially want to mend their clothes, but there’s no easy way of finding or accessing that service,” she says. “With this next generation, you need to meet them where they are.”

And where they are, Allen says, is on their phones.

MendIt is completing a pilot program with one mender — Connect Community in Gulfton area — in partnership with St. Luke's Gethsemane on Bellaire in Sharpstown. She also hopes to tap into a local artist who can help with customization — like embroidery, for instance. Click here to read more.

Miguel Calatayud, CEO of iwi

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

Miguel Calatayud feels like he has the perfect storm of a product. Not only does his company iwi's nutritional supplement have a sustainability focus, it's also just a very competitive product in the marketplace. The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2.

"We've been growing significantly for one main reason," Calatayud says. "It works."

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the Houston Innovators podcast.Click here to read more.

Tatiana Fofanova, co-founder and CEO of Koda Health

Tatiana Fofanova, co-founder and CEO of Koda, closed recent funding for the digital health startup. Image via LinkedIn

Tatiana Fofanova, Koda co-founder and CEO, has something to celebrate. The Houston-based startup announced this month that it raised $3.5 million in its latest seed round. The funding will be used to help the digital advanced care planning company double the size of its team in the next six months.

"Koda Health helps vulnerable people navigate and communicate difficult decisions about their health care journey. So, when hiring, we look for empathetic people who are phenomenal communicators," Tatiana Fofanova, Koda co-founder and CEO, says in a statement.

The Koda team will also use the funds to expand its operations to all 50 states. According to the statement, the team plans to focus on low-resource communities and operating in different languages. Click here to read more.

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

How this Houston innovator plans to make a sustainable impact — one algae farm at a time

Houston innovators podcast episode 120

If there's one thing Miguel Calatayud is passionate about it's conscious capitalism — and specifically that his company, iwi, a Houston-based food and nutritional supplement company, is striking the perfect balance between impact and profit.

The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2. Calatayud says the farms even area able to reuse 98 percent of the water involved in the process.

"In the past, you had to choose between making an impact and making a profit," Calatayud says on this week's episode of the Houston Innovators Podcast. "In our case, the way we built the company and the business model we put together, it's actually the opposite. The bigger the impact we make, the bigger the business we're creating."

With all this sustainability to boast about, Calatayud says it's not even the best part. Iwi's products, which include Omega-3 supplements, multivitamins, and even a forthcoming protein — all made from the farmed algae, are also very competitive products in the market.

"We've been growing significantly for one main reason," Calatayud says." It works."

"That's what's really driving the growth in the company because once a customer starts taking iwi, they don't go back to whatever they were taking before," Calatayud continues on the show.

Calatayud says iwi is ready to expand more internationally. The company recently closed an $8 million deal — $5.5 million in senior secured term debt and a $2.5 million direct equity investment — with GP Capital Partners, an investor and strategic partner for the company. The influx of funding will help iwi accelerate sales of its existing products and ramp up development, marketing, and growth of new protein-based product, according to the release. Iwi will also enter new international markets.

"What we are going to do with [GP] and other investors that we have is to take this brand to the next level," Calatayud says. "Last year, we grew 91 percent. This year, we are planning to grow around 200 percent."

Calatayud says the pond systems iwi operates are replicable, and as the company grows he could see building these types of algae farms across the world and even in the Middle East, creating jobs and opportunities globally.

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


Houston researchers make headway on affordable, sustainable sodium-ion battery

Energy Solutions

A new study by researchers from Rice University’s Department of Materials Science and NanoEngineering, Baylor University and the Indian Institute of Science Education and Research Thiruvananthapuram has introduced a solution that could help develop more affordable and sustainable sodium-ion batteries.

The findings were recently published in the journal Advanced Functional Materials.

The team worked with tiny cone- and disc-shaped carbon materials from oil and gas industry byproducts with a pure graphitic structure. The forms allow for more efficient energy storage with larger sodium and potassium ions, which is a challenge for anodes in battery research. Sodium and potassium are more widely available and cheaper than lithium.

“For years, we’ve known that sodium and potassium are attractive alternatives to lithium,” Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering at Rice, said in a news release. “But the challenge has always been finding carbon-based anode materials that can store these larger ions efficiently.”

Lithium-ion batteries traditionally rely on graphite as an anode material. However, traditional graphite structures cannot efficiently store sodium or potassium energy, since the atoms are too big and interactions become too complex to slide in and out of graphite’s layers. The cone and disc structures “offer curvature and spacing that welcome sodium and potassium ions without the need for chemical doping (the process of intentionally adding small amounts of specific atoms or molecules to change its properties) or other artificial modifications,” according to the study.

“This is one of the first clear demonstrations of sodium-ion intercalation in pure graphitic materials with such stability,” Atin Pramanik, first author of the study and a postdoctoral associate in Ajayan’s lab, said in the release. “It challenges the belief that pure graphite can’t work with sodium.”

In lab tests, the carbon cones and discs stored about 230 milliamp-hours of charge per gram (mAh/g) by using sodium ions. They still held 151 mAh/g even after 2,000 fast charging cycles. They also worked with potassium-ion batteries.

“We believe this discovery opens up a new design space for battery anodes,” Ajayan added in the release. “Instead of changing the chemistry, we’re changing the shape, and that’s proving to be just as interesting.”

---

This story originally appeared on EnergyCapitalHTX.com.

View All Listings